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Fig 1. FF-ANN scheme. 
 
Results: An inverse correlation of the radio-sensitivity 
parameter assessed by the model was found with respect the 
dR2* (-0.65) for the Oxy group. A further subdivision 
according to positive and negative values of dR2* showed a 
larger average radio-sensitivity for the Oxy rats with <0 and a 
significant difference in the two distributions according to 
the Wilcoxon-Mann-Whitney test (p<0.05). Finally, the 
Pearson correlation coefficient (R^2>0.9) revealed a strong 
agreement of the FF-ANN output with the target radio-
sensitivity. 
 
Conclusion: These preliminary findings support the 
hypothesis that the change in the R2* can be related to tumor 
oxygenation and, consequently, to its radio-sensitivity. In 
particular, the sign of the tendency is in accordance with the 
fact that an oxygenation increase reduces the tumor 
relaxation rate as reported in the literature. Moreover, the 
different distributions of α, outlined in the Oxy subgroups 
according to the dR2*, suggest that some subjects would 
benefit from oxygen inhalation more than others, reasonably 
due to their initial vascularization. Finally, the performance 
of the FF-ANN is promising, although it would require a larger 
dataset to validate its prediction ability. 
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Purpose or Objective: Administration of monoclonal 
antibody Epidermal Growth Factor Receptor (MoAb-EGFr) 
inhibitor every week during Radiotherapy (RT) of head and 
neck cancer (HNC) has shown improved outcomes as 
compared to RT alone in terms of locoregional disease 
control, progression free and overall survival, thanks to its 
radiosensitizing effect. MoAb-EGFr concentration varies day 
by day after injection, and radiosensitizing effect 
accordingly. A radiobiological (RB) model accounting for this 
variation (Pedicini, et al. Radiat Oncol. 2012;7:143) can be 
applied to shorten the treatment by optimizing daily RT dose, 
still maintaining unchanged the biological effect on the 
tumour (in terms of surviving cells) as compared to standard 
RT (7 weeks, PTV1: GTV, 70Gy; PTV2 = GTV+margin, 63Gy; 
PTV3: lymph nodes: 58.1Gy) and potentially reducing healthy 
tissue toxicity. In this study, such RB model was adopted in 
the clinical protocol FAMOSO (Frazionamento Accelerato 
MOdulato in SIB-IMRT dei tumori testa-collO) for the 
treatment of HNC tumours with simultaneous integrated 
boost (SIB), aiming to test the feasibility of accelerated 
modulated fractioning and to assess toxicity and response 
rate. 
 
Material and Methods: From literature data, showing that 
higher concentrations of MoAb-EGFr correspond to steeper 
tumor cell survival curves, radiobiological parameters were 
derived and included in the RB model to obtain the daily dose 
to be delivered to each target volume. To date, 2 of the 10 
expected pts (pt1: cT4cN1 oropharyngeal; pt2: cT2 cN3 
supraglottic squamous cell carcinoma) have been recruited 
and treated with SIB-IMRT with a curative intent. 
 
Results: The RB model suggested a 6 week treatment with 
daily increasing dose/fractions as follows: PTV1: 1.70, 1.95, 
2.15, 2.30, 2.35Gy; PTV2: 1.50, 1.75, 1.95, 2.05, 2.10Gy; 
PTV3: 1.40, 1.60, 1.80, 1.90, 1.95Gy. Both pts recruited in 
the FAMOSO protocol concluded the radiation treatment : pt1 
with no change of the planned schedule; pt2 with 
interruption of MoAb-EGFr after the 5th administration and, 
consequently, the last 10 RT fractions of RT were 
administered with standard fractionation. The total dose to 
the PTV1 were 62.7 and 61.8 Gy, respectively. Maximun 
acute skin and mucosal toxicity was G3. With a follow up of 6 
and 2 months, a partial response was obtained for pt1, while 
pt2 is still under evaluation. 
 
Conclusion: New treatment strategies, even accelerated, are 
feasible when combining RT with radiosensitizing drugs. The 
RB model is adequate to set up the treatment provided 
radiobiological parameters are available from clinical data. 
The preliminary clinical data of the protocol FAMOSO give 
encouraging results, suggesting that the treatment schedule 
is feasible with acceptable acute toxicity. Longer follow up is 
needed to confirm toxicity findings and assess response rate, 
and of course more patients have to be studied. 
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Purpose or Objective: Variability in the contouring of gross 
tumour and the derived planning target volumes (PTVs) 
between clinicians is well-known in radiotherapy. This study 
aims to quantify the impact of variability in contouring in 
terms of tumour control and normal tissue toxicity in Liver 
SBRT. 
 
Material and Methods: The National Radiotherapy Trials 
Quality Assurance (RTTQA) Group planning benchmark case 
for the ABC07 Trial was used (addition of stereotactic body 
radiotherapy to systemic chemotherapy in locally advanced 
biliary tract cancers; CRUK A18752, sponsor University 
College London). 12 centers performed contouring 
independently using radiotherapy trial protocol as per RTTQA 
pre-trial QA process. Each centre applied margins to derive 
PTV as per local practice. A standardised Volumetric 
Modulated Arc Therapy (VMAT) plan was produced based on 
gold standard contours and applied to all 12 sets of submitted 
contours aiming to deliver 50Gy in 5 fractions. However, due 
to large GTV this was unavoidably de-escalated to 40Gy to 
meet trial mandatory mean non-GTV Liver constraint. 
Tumour control was assessed through biologically effective 
dose (BED) to 98, 95 and 90% of the gold standard PTV. 65Gy 
BED, although disappointingly low for SBRT, was considered 
